These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 21319202)

  • 1. Nuclear receptors in liver disease.
    Wagner M; Zollner G; Trauner M
    Hepatology; 2011 Mar; 53(3):1023-34. PubMed ID: 21319202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bile acids as regulators of hepatic lipid and glucose metabolism.
    Trauner M; Claudel T; Fickert P; Moustafa T; Wagner M
    Dig Dis; 2010; 28(1):220-4. PubMed ID: 20460915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting nuclear bile acid receptors for liver disease.
    Trauner M; Baghdasaryan A; Claudel T; Fickert P; Halilbasic E; Moustafa T; Zollner G
    Dig Dis; 2011; 29(1):98-102. PubMed ID: 21691114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear receptors as new perspective for the management of liver diseases.
    Trauner M; Halilbasic E
    Gastroenterology; 2011 Apr; 140(4):1120-1125.e1-12. PubMed ID: 21334334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interaction of hepatic lipid and glucose metabolism in liver diseases.
    Bechmann LP; Hannivoort RA; Gerken G; Hotamisligil GS; Trauner M; Canbay A
    J Hepatol; 2012 Apr; 56(4):952-64. PubMed ID: 22173168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.
    Moustafa T; Fickert P; Magnes C; Guelly C; Thueringer A; Frank S; Kratky D; Sattler W; Reicher H; Sinner F; Gumhold J; Silbert D; Fauler G; Höfler G; Lass A; Zechner R; Trauner M
    Gastroenterology; 2012 Jan; 142(1):140-151.e12. PubMed ID: 22001865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.
    Xu JY; Li ZP; Zhang L; Ji G
    World J Gastroenterol; 2014 Oct; 20(37):13493-500. PubMed ID: 25309079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease.
    Wei J; Qiu DK; Ma X
    J Dig Dis; 2009 May; 10(2):85-90. PubMed ID: 19426389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [FXR and its influence on hepatobiliary and gastrointestinal diseases].
    Xu YJ; Zhao C; Yin YR
    Sheng Li Ke Xue Jin Zhan; 2013 Dec; 44(6):420-4. PubMed ID: 24665740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bile acid receptors in non-alcoholic fatty liver disease.
    Li Y; Jadhav K; Zhang Y
    Biochem Pharmacol; 2013 Dec; 86(11):1517-24. PubMed ID: 23988487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile acid transporters and regulatory nuclear receptors in the liver and beyond.
    Halilbasic E; Claudel T; Trauner M
    J Hepatol; 2013 Jan; 58(1):155-68. PubMed ID: 22885388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yangonin modulates lipid homeostasis, ameliorates cholestasis and cellular senescence in alcoholic liver disease via activating nuclear receptor FXR.
    Kong L; Dong R; Huang K; Wang X; Wang D; Yue N; Wang C; Sun P; Gu J; Luo H; Liu K; Wu J; Sun H; Meng Q
    Phytomedicine; 2021 Sep; 90():153629. PubMed ID: 34304130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear receptors as therapeutic targets in cholestatic liver diseases.
    Zollner G; Trauner M
    Br J Pharmacol; 2009 Jan; 156(1):7-27. PubMed ID: 19133988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear receptors in regenerating liver and hepatocellular carcinoma.
    Vacca M; Degirolamo C; Massafra V; Polimeno L; Mariani-Costantini R; Palasciano G; Moschetta A
    Mol Cell Endocrinol; 2013 Apr; 368(1-2):108-19. PubMed ID: 22789748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors.
    Chiang JY
    Am J Physiol Gastrointest Liver Physiol; 2003 Mar; 284(3):G349-56. PubMed ID: 12576301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
    Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
    Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation.
    Wagner M; Zollner G; Trauner M
    Hepatology; 2008 Nov; 48(5):1383-6. PubMed ID: 18972560
    [No Abstract]   [Full Text] [Related]  

  • 19. Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases.
    Arrese M; Karpen SJ
    Clin Pharmacol Ther; 2010 Apr; 87(4):473-8. PubMed ID: 20200515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.
    Arab JP; Karpen SJ; Dawson PA; Arrese M; Trauner M
    Hepatology; 2017 Jan; 65(1):350-362. PubMed ID: 27358174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.